Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

What are editors for?

Burch D, Mafham M, Yudkin JS.

Lancet. 2012 Jun 16;379(9833):2240. doi: 10.1016/S0140-6736(12)60977-5. No abstract available.

PMID:
22704168
2.

Insulin degludec: a new ultra-longacting insulin.

Tahrani AA, Bailey CJ, Barnett AH.

Lancet. 2012 Apr 21;379(9825):1465-7. doi: 10.1016/S0140-6736(12)60527-3. No abstract available.

PMID:
22521058
3.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AM, Pei H, Bode B; BEGIN Basal-Bolus Type 1 Trial Investigators..

Lancet. 2012 Apr 21;379(9825):1489-97. doi: 10.1016/S0140-6736(12)60204-9.

PMID:
22521071
4.

Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.

Nimri R, Lebenthal Y, Shalitin S, Benzaquen H, Demol S, Phillip M.

Pediatr Diabetes. 2013 May;14(3):196-202. doi: 10.1111/pedi.12012.

PMID:
23289822
6.

Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.

Dieuzeide G, Chuang LM, Almaghamsi A, Zilov A, Chen JW, Lavalle-González FJ.

Prim Care Diabetes. 2014 Jul;8(2):111-7. doi: 10.1016/j.pcd.2013.07.005.

PMID:
23953707
7.

Mixing insulin aspart with detemir does not affect glucose excursion in children with type 1 diabetes.

Nguyen TM, Renukuntla VS, Heptulla RA.

Diabetes Care. 2010 Aug;33(8):1750-2. doi: 10.2337/dc10-0169.

8.

Audit of insulin detemir in pregnancy: a retrospective case series.

Shenoy VV, Cook SJ, Parry AF, McIntyre HD.

Diabet Med. 2012 Jul;29(7):958-9. doi: 10.1111/j.1464-5491.2012.03580.x. No abstract available.

PMID:
22248154
9.

Criteria influencing the choice of starting insulin regimen in patients with type 2 diabetes in routine clinical practice: baseline data from the Algerian cohort of the A₁chieve study.

Malek R, Arbouche Z, Bachaoui M, Zinai S, Dahaoui A, Senoussaoui S, Salah-Mansour A.

Diabetes Res Clin Pract. 2013 Aug;101 Suppl 1:S45-9. doi: 10.1016/S0168-8227(13)70018-4.

PMID:
23958572
10.

Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naïve subjects with type 2 diabetes.

Yang W, Xu X, Liu X, Yang G, Seino Y, Andersen H, Jinnouchi H.

Curr Med Res Opin. 2013 Dec;29(12):1599-608. doi: 10.1185/03007995.2013.838155.

PMID:
23998560
11.
12.

Safety and effectiveness of insulin analogues in type 2 diabetic patients from Algeria: a sub-analysis of the A₁chieve study.

Malek R, Arbouche Z, Dahaoui A, Bachaoui M.

Diabetes Res Clin Pract. 2013 Aug;101 Suppl 1:S15-26. doi: 10.1016/S0168-8227(13)70015-9.

PMID:
23958568
13.

Safety and effectiveness of insulin analogues in Moroccan patients with type 2 diabetes: a sub-analysis of the A₁chieve study.

Chraibi A, Ajdi F, Belkhadir J, El Ansari N, Marouan F, Farouqi A.

Diabetes Res Clin Pract. 2013 Aug;101 Suppl 1:S27-36. doi: 10.1016/S0168-8227(13)70016-0.

PMID:
23958569
14.

The future of care for type 1 diabetes.

Nathan DM, Russell S.

CMAJ. 2013 Mar 5;185(4):285-6. doi: 10.1503/cmaj.130011. No abstract available.

15.

Ultra-long-acting insulins for a lifestyle-related pandemic.

Kudva YC, Basu A.

Lancet. 2011 Mar 12;377(9769):880-1. doi: 10.1016/S0140-6736(11)60097-4. No abstract available.

PMID:
21396704
16.

Exploring insulin analogue safety and effectiveness in a Maghrebian cohort with type 2 diabetes: results from the A₁chieve study.

Belhadj M, Dahaoui A, Jamoussi H, Farouqi A.

Diabetes Res Clin Pract. 2013 Aug;101 Suppl 1:S4-14. doi: 10.1016/S0168-8227(13)70014-7.

PMID:
23958571
17.

Biphasic insulin aspart 30 for the treatment of type 1 diabetes mellitus.

Velásquez-Mieyer PA, Neira CP.

Expert Opin Pharmacother. 2008 Sep;9(13):2377-82. doi: 10.1517/14656566.9.13.2377 . Review.

PMID:
18710361
18.

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.

Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR; BEGIN® Basal-Bolus Type 1 trial investigators..

Diabet Med. 2013 Nov;30(11):1293-7. doi: 10.1111/dme.12243.

19.

Insulin degludec: a new insulin for today?

Hitman GA.

Diabet Med. 2013 Nov;30(11):1267. doi: 10.1111/dme.12319. No abstract available.

PMID:
24134602
20.

New long-acting insulin analogs: from clamp studies to clinical practice.

Bolli GB, DeVries JH.

Diabetes Care. 2015 Apr;38(4):541-3. doi: 10.2337/dc14-2314. No abstract available.

PMID:
25805863
Items per page

Supplemental Content

Support Center